Details of the Drug

General Information of Drug (ID: DMSIVND)

Drug Name

Hydroxychloroquine

Synonyms

Hidroxicloroquina; Hidroxicloroquina [INN-Spanish]; Hydroxychlorochin; Gen-Hydroxychloroquine 200mg Tablets; HCQ; Hydroxychloroguine; Hydroxychloroquine (INN);Hydroxychloroquine [INN:BAN]; Hydroxychloroquine Sulfate (1:1) Salt; Hydroxychloroquinum; Hydroxychloroquinum [INN-Latin]; Idrossiclorochina; Idrossiclorochina [DCIT]; Oxichlorochinum; Oxichloroquine; Oxychlorochin; Oxychloroquine; Plaquenil (TN); Polirreumin; Polirreumin (TN); Quensyl; WIN 1258

Indication

Disease Entry	ICD 11	Status	REF
Chronic renal failure	GB61.Z	Approved	[1]
Malaria	1F40-1F45	Approved	[2]
Plasmodium falciparum malaria	1F40	Approved	[1]
Plasmodium malariae malaria	N.A.	Approved	[1]
Plasmodium ovale malaria	N.A.	Approved	[1]
Systemic lupus erythematosus	4A40.0	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
Colon cancer	2B90.Z	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antimalarials

Affected Organisms

Plasmodium

ATC Code

P01BA02: Hydroxychloroquine

P01BA: Aminoquinolines

P01B: ANTIMALARIALS

P01: ANTIPROTOZOALS

P: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

335.9

Logarithm of the Partition Coefficient (xlogp)

3.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: 74% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [6]
Elimination: 27% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 850 hours [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 29.7725 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.57% [6]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 700 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 200 mg/mL [4]

Chemical Identifiers

Formula: C18H26ClN3O
IUPAC Name: 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
Canonical SMILES: CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
InChI: InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
InChIKey: XXSMGPRMXLTPCZ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3652
ChEBI ID: CHEBI:5801
CAS Number: 118-42-3
UNII: 4QWG6N8QKH
DrugBank ID: DB01611
TTD ID: D0OJ4L
VARIDT ID: DR00449
INTEDE ID: DR0837
ACDINA ID: D00316

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 7 (TLR7)	TTRJ1K4	TLR7_HUMAN	Antagonist	[8]
HUMAN glycosylation of host receptor (GHR)	TTZGK1R	.	Inhibitor	[9]
HUMAN pH-dependent viral fusion/replication (pH-DVF/R)	TTD16BI	.	Inhibitor	[9]
HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)	TT3A1EZ	.	Inhibitor	[10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Gene/Protein Processing	[13]
7-dehydrocholesterol reductase (DHCR7)	OTLILBUI	DHCR7_HUMAN	Gene/Protein Processing	[13]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Gene/Protein Processing	[14]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Gene/Protein Processing	[13]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[15]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Gene/Protein Processing	[16]
C-X-C motif chemokine 10 (CXCL10)	OTTLQ6S0	CXL10_HUMAN	Gene/Protein Processing	[17]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Gene/Protein Processing	[18]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[18]
Cathepsin B (CTSB)	OTP9G5QB	CATB_HUMAN	Protein Interaction/Cellular Processes	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Chronic renal failure

ICD Disease Classification

GB61.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Toll-like receptor 7 (TLR7)	DTT	TLR7	3.32E-25	0.44	0.88
Breast cancer resistance protein (ABCG2)	DTP	BCRP	5.18E-17	3.16E-01	7.14E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.29E-36	-3.75E-01	-1.06E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Hydroxychloroquine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Lumefantrine.	Malaria [1F40-1F45]	[19]
-----------

Coadministration of a Drug Treating the Disease Different from Hydroxychloroquine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[20]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Midostaurin.	Acute myeloid leukaemia [2A60]	[21]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Arn-509.	Acute myeloid leukaemia [2A60]	[22]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[21]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Oliceridine.	Acute pain [MG31]	[21]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Ivabradine.	Angina pectoris [BA40]	[22]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Dronedarone.	Angina pectoris [BA40]	[23]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[21]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Levalbuterol.	Asthma [CA23]	[24]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Hydroxychloroquine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Retigabine.	Behcet disease [4A62]	[21]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Eribulin.	Breast cancer [2C60-2C6Y]	[21]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Hydroxychloroquine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Bosutinib.	Breast cancer [2C60-2C6Y]	[21]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[21]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Pasireotide.	Cushing syndrome [5A70]	[21]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Osilodrostat.	Cushing syndrome [5A70]	[21]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Hydroxychloroquine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[19]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Hydroxychloroquine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[19]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[21]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Deutetrabenazine.	Dystonic disorder [8A02]	[21]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Ingrezza.	Dystonic disorder [8A02]	[21]
Methsuximide	DM6L5VO	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Methsuximide.	Epilepsy/seizure [8A61-8A6Z]	[19]
Stiripentol	DMMSDOY	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Stiripentol.	Epilepsy/seizure [8A61-8A6Z]	[19]
Brivaracetam	DMSEPK8	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Brivaracetam.	Epilepsy/seizure [8A61-8A6Z]	[19]
Lacosamide	DMVM6QR	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Lacosamide.	Epilepsy/seizure [8A61-8A6Z]	[19]
Rufinamide	DMWE60C	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[19]
Eslicarbazepine	DMZREFQ	Moderate	Antagonize the effect of Hydroxychloroquine when combined with Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[19]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Hydroxychloroquine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[19]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Hydroxychloroquine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[19]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Hydroxychloroquine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[26]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Hydroxychloroquine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Hydroxychloroquine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[23]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[23]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Crizotinib.	Lung cancer [2C25]	[21]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Ceritinib.	Lung cancer [2C25]	[21]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Osimertinib.	Lung cancer [2C25]	[21]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Selpercatinib.	Lung cancer [2C25]	[21]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Hydroxychloroquine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[19]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Vemurafenib.	Melanoma [2C30]	[23]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and LGX818.	Melanoma [2C30]	[21]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Hydroxychloroquine due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[23]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Panobinostat.	Multiple myeloma [2A83]	[27]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Siponimod.	Multiple sclerosis [8A40]	[19]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Fingolimod.	Multiple sclerosis [8A40]	[23]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Hydroxychloroquine and Ozanimod.	Multiple sclerosis [8A40]	[28]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Romidepsin.	Mycosis fungoides [2B01]	[21]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Hydroxychloroquine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[19]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[23]
E-2007	DMJDYNQ	Moderate	Antagonize the effect of Hydroxychloroquine when combined with E-2007.	Neuropathy [8C0Z]	[19]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Entrectinib.	Non-small cell lung cancer [2C25]	[21]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Lofexidine.	Opioid use disorder [6C43]	[21]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Triclabendazole.	Parasitic worm infestation [1F90]	[21]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Pimavanserin.	Parkinsonism [8A00]	[21]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[29]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Lefamulin.	Pneumonia [CA40]	[30]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Hydroxychloroquine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[19]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Degarelix.	Prostate cancer [2C82]	[22]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and ABIRATERONE.	Prostate cancer [2C82]	[22]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Enzalutamide.	Prostate cancer [2C82]	[22]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Relugolix.	Prostate cancer [2C82]	[22]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Iloperidone.	Schizophrenia [6A20]	[21]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Amisulpride.	Schizophrenia [6A20]	[21]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Asenapine.	Schizophrenia [6A20]	[21]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Hydroxychloroquine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[19]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[21]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[23]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[22]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Pitolisant.	Somnolence [MG42]	[21]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[21]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Hydroxychloroquine and Lenvatinib.	Thyroid cancer [2D10]	[21]
-----------


⏷ Show the Full List of 75 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Hydroxychloroquine 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Hydroxychloroquine FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7198).
3	ClinicalTrials.gov (NCT04341727) Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection (WU352). U.S. National Institutes of Health.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
9	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
10	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
11	MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
12	Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018 Jun;365(3):447-459.
13	Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J Cell Mol Med. 2018 Feb;22(2):873-882. doi: 10.1111/jcmm.13373. Epub 2017 Oct 3.
14	Attenuation of chloroquine and hydroxychloroquine on the invasive potential of bladder cancer through targeting matrix metalloproteinase 2 expression. Environ Toxicol. 2021 Nov;36(11):2138-2145. doi: 10.1002/tox.23328. Epub 2021 Jul 19.
15	Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene. 2003 Jun 19;22(25):3927-36. doi: 10.1038/sj.onc.1206622.
16	Reactive oxygen species mediate chloroquine-induced expression of chemokines by human astroglial cells. Glia. 2004 Jul;47(1):9-20. doi: 10.1002/glia.20017.
17	Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015 Mar;35(3):143-56. doi: 10.1089/jir.2014.0038. Epub 2014 Oct 16.
18	Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol. 2006 Jun;144(3):503-11. doi: 10.1111/j.1365-2249.2006.03070.x.
19	Cerner Multum, Inc. "Australian Product Information.".
20	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
21	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
22	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
23	Canadian Pharmacists Association.
24	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
25	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
26	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
27	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
28	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
29	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
30	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.